期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HIV-1 gp41 NHR结合性环肽的研究

Study of the cyclic peptide binding to HIV-1 gp41 NHR
下载PDF
导出
摘要 目的筛选可与HIV-1 gp41 NHR结合的环肽,为研制抗HIV-1早期感染的小分子药物奠定基础。方法采用P+LS方法,用源于gp41 NHR的合成肽N36肽筛选噬菌体环七肽库,ELISA鉴定噬菌体克隆,根据阳性克隆的DNA序列,合成环肽并鉴定其与N36肽结合。结果经3轮筛选、鉴定,得到11个和N36肽结合的噬菌体克隆。DNA测序并推导氨基酸序列,表明这11个克隆展示同一序列CDRHQHKRC。根据此序列合成的环肽NA(Biotin-SACDRHQHKRCGG)经与载体蛋白BSA偶联后,ELISA鉴定表明交联物可特异地与N36肽结合,这种结合可被游离N36肽、以及源于gp41 CHR的肽C34抑制。结论SACDRHQHKRCGG环肽为HIV-1 gp41 NHR结合肽。 Objective To find small molecular that can lead to inhibition of HIV-1 infection in early stage by screening the cyclic peptide that can bind to HIV-1 gp41 NHR from phage display peptide library. Methods C7C phage displayed peptide library was biopanning by using the P＋ LS method with target molecule of N36 peptide derived from the gp41 NHR. Phage clones were identified by ELISA. Based on the DNA sequence of positive clones, the cyclic peptide was synthesized. The binding between N36 and the cyclic peptide was identified. Restilts After 3 rounds of screening, 11 phage clones were identified as the positive clones. All these clones shared a unique amino acid sequenee--CDRHQHKRC, which was amed NA peptide. The modified NA peptide （Biotin-SACDRHQHKRCGG） was synthesized and conjugated with BSA as carder. The binding between NA-BSA conjugate and peptide N36 was blocked by soluble peptides N36 and C34 （derived from gp41 CHR）. Conclusion The cyclic peptide SACDRHQHKRCGG is the HIV-1 gp41 NHR binding peptide.
作者 刘北一 朱平 姜世勃 富宁
机构地区 南方医科大学基础医学院免疫学教研室 美国纽约血液中心LFK研究所
出处 《免疫学杂志》 CAS CSCD 北大核心 2006年第1期1-4,共4页 Immunological Journal
基金 国家自然科学基金海外合作基金(30028021) 广州市科技计划项目(2002E-E0421)资助
关键词 HIV-1 噬菌体展示肽库 N末端疏水重复区(NHR) 结合肽 HIV-1 Phage display peptide library N-terminal hydmphobic/heptad repeatd region（NHR） Binding peptide
分类号 R965.1 [医药卫生—药理学]
  • 相关文献

参考文献12

  • 1Chan DC,Fass D,Berger JM,et al.Core structure of gp41from the HIV envelope glycoprotein[ J ].Cell,1997,89 (2):263-273.
  • 2Chan DC,Chutkowski CT,Kim PS.Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target[ J ].Proc Natl Acad Sci USA,1998,95 (26):15 613-15 617.
  • 3Jiang S,Lin K,Strick N,et al.HIV-1 inhibition by a peptide[J].Nature,1993,365 (6 442):113.
  • 4Wild CT,Shugars DC,Greenwell TK,et al.Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection[J].Proc Natl Acad Sci USA,1994,91 (21):9 770-9 774.
  • 5Eron JJ,Gulick RM,Bartlett JA,et al.Short-term safety and antiretroviral activity of T-1249,a second-generation fusion inhibitor of HIV[J].J Infect Dis,2004,189 (6):1 075-1083.
  • 6Kilby JM,Hopkins S,Venetta TM,et al.Potent suppression of HIV-1 replication in humans by T-20,a peptide inhibitor of gp41-mediated virus entry[J].Na Med,1998,4 (11):1 302-1 307.
  • 7Lu J,Sista P,Giguel F,et al.Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20)[ J ].J Virol,2004,78 (9):4 628 -4 637.
  • 8Debnath AK,Radigan L,Jiang S.Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1[J].J Med Chem,1999,42 (17):3203-3209.
  • 9Eckert DM,Malashkevich VN,Hong LH,et al.Inhibiting HIV-1 entry:discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket[J].Cell,1999,99 (1):103 -115.
  • 10Sia SK,Carr PA,Cochran AG,et al.Short constrained peptides that inhibit HIV-1 entry[J].Proc Natl Acad Sci USA,2002,99 (23):14 664-14 669.

二级参考文献15

  • 1郑红,朱锡华.HIV疫苗的研究策略及其进展[J].免疫学杂志,2000,16(z1):59-62. 被引量：9
  • 2[1]Eckert D M,Kim P S.Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region [J].Proc Natl Acad Sci USA,2001;98(20):11178.
  • 3[2]Lu M,Blacklow S C,Kim P S.A trimeric structural domain of the HIV-1 transmembrane glycoprotein [J].Nat Struct Biol,1995;2(12):1075.
  • 4[3]Jiang S,Lin K,Strick et al.HIV-1 inhibition by a peptide [J].Nature,1993;365:113.
  • 5[4]Wild C T,Shugars D C,Greenwell T K et al.Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type I gp41 are potent inhibitors of virus infection [J].Proc Natl Acad Sci USA,1994;91:9770.
  • 6[5]Kilb J M,Hopkins S,Venetta T M et al.Potent suppression of HIV-1 replication in humans by T-20,a peptide inhibitor of gp41-mediated virus entry [J].Nat Med,1998;4(11):1302.
  • 7[6]Kim P S,Root M J,Kay M S.Protein design of an HIV-1 entry inhibitor [J].Science,2001;291:884.
  • 8[7]Debnath A K,Radigan L,Jiang S B.Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1 [J].J Med Chem,1999;42:3203.
  • 9[8]Eckert D M,Malashkevich V N,Kim P S et al.Inhibiting HIV-1 entry:discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket [J].Cell,1999;99:103.
  • 10[10]Weissenhorn W,Wharton S A,Calder L J et al.The ectodomain of HIV-1 env subunit gp41 forms a soluble,alpha-helical,rodlike oligomer in the absence of gp120 and the N-terminal fusion peptide [J].EMBO J,1996;15:1507.

共引文献4

免疫学杂志
2006年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部